Expanding the Lens on Dementia Risk: A Gender-Inclusive Call to Action

27 September, 2025 

A new article published in The Lancet eBioMedicine builds on the 2024 Lancet Commission Report by proposing a more inclusive global framework for dementia prevention. While the Commission identified 14 modifiable risk factors accounting for 45% of global dementia cases, this new analysis highlights four additional socioeconomic and health-related risks—poverty, wealth shocks, income inequality, and HIV infection—that disproportionately affect women and underserved populations.

The authors argue that integrating these factors could raise the proportion of preventable dementia cases to 65%, while also correcting gender imbalances in current models. Notably, although women bear the majority of dementia burden globally, 57% of the Commission’s identified risk factors are more prevalent in men. By recalibrating the risk profile, the expanded model reveals that 56% of modifiable risks disproportionately impact women.

This research underscores the urgent need for gender-sensitive, culturally adaptive strategies—especially in low- and middle-income countries—where dementia prevalence is projected to surge.

The Women’s Brain Foundation supports this call for equity-driven prevention, advocating for policies that address the social determinants of brain health and empower women across the lifespan.

Read the full article here.

We are here to transform medicine and healthcare towards precision medicine. Right now, there is a critical need for your support. Donate today and help us continue to study Sex and Gender differences impacting brain and mental diseases.

Health begins with human beings, individuals – men and women are different when it comes to brain and mental disease frequency, severity, symptomatology, risk factors and even response to treatments. Thanks to the gifts from supporters like you the scientific community is starting to take note. We have shown the world that in diseases like Alzheimer’s for instance, disease progression is faster in women than men and women show different levels of biomarkers.

Our goal is to clearly identify such differences in diseases, diagnostic, and treatments, as well as novel technologies, and leverage them for better solutions. We ask for better clinical outcomes, better care, and innovative artificial intelligence (AI)-based solutions. Sex and gender differences are the first steps towards precision medicine, which acknowledges the specific needs of each patient. Our ultimate ambition is the realisation of the Research Institute for Sex and Gender Precision Medicine.